OCT 22, 2020 12:05 PM PDT

Molecular Testing of NSCLC Biopsies: Making mountains out of molehills

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
    Biography



      Dr. Kletecka a board certified and fellowship trained Molecular Pathologist. She performed her residency training in anatomic and clinical pathology at Case Western Reserve University Hospitals of Cleveland and fellowship subspecialty training in Molecular Genetic Pathology and Surgical Pathology at TriCore Reference Laboratories and the University of New Mexico Hospital. She currently serves as the Medical Director of the VISN22 Molecular Diagnostics Laboratory in Los Angeles where she and her team implemented molecular oncology testing by next generation sequencing for the VA system.


    Abstract

    Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients.  However, NCSLC biopsies are typically very small and require multiple types of analysis for complete workup including H&E for diagnosis, IHC for classification, and FISH, IHC and NGS for biomarker testing.  This talk will focus on overcoming some of the challenges laboratories face when working with such a limited amount of tissue and how NGS can help.

    Learning Objectives:

    1. Review clinical guidelines for molecular testing of testing of non-small cell lung cancer specimens

    2. Become familiar with recommendations for biopsy tissue stewardship 

    3. How NGS can be used for molecular testing of NSCLC biopsies


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    Loading Comments...
    Show Resources